Press Release Stockholm, Sweden, January 12, 2009 Elekta has received approval from the Chinese authority SFDA (State Food and Drug Administration) to sell its linear accelerator Elekta Compact™ in China.
Elekta Compact™ is a competitive linear accelerator for high quality conventional radiotherapy, configured for countries in need of rapid build-up of additional treatment capacity. Elekta Compact is based on a combination of technology from Elekta and from the product platform developed by the Chinese company BMEI, which Elekta acquired in 2006.
− There is a large potential for Elekta Compact in China, where there is shortage of good cancer treatment. The number of linear accelerators is less than one per million inhabitants and a large part of the existing systems needs to be replaced. Further, Elekta Compact is the ideal treatment system when replacing existing Cobalt units as the platform allows for further growth and expansion, says Tomas Puusepp, President and CEO of Elekta.
In May 2008 Elekta received SFDA approval to export Elekta Compact outside China and in June 2008 Elekta completed the process of adding CE marking, allowing Elekta Compact to be marketed in Europe, Latin America and Asia.